Adagene (FRA:978) Other Current Payables: €8.84 Mil (As of Dec. 2025)


FRA:978 Adagene Inc FRA:978
42 GF Score
Price €3.26
GF Value €11.95
! 3 Warning Signs
View Full Analysis

What is Adagene Other Current Payables?

Adagene FRA:978 -0.61% 42 Other Current Payables is €8.84 Mil as of Dec. 2025. GuruFocus rates FRA:978 with a GF Score™ of 42/100 and a GF Value™ of €11.95. The stock has 3 warning signs investors should review.

Adagene's Other Current Payables for the quarter that ended in Dec. 2025 was €8.84 Mil.

Adagene's quarterly Other Current Payables declined from Dec. 2024 (€12.60 Mil) to Jun. 2025 (€12.53 Mil) and declined from Jun. 2025 (€12.53 Mil) to Dec. 2025 (€8.84 Mil).

Adagene's annual Other Current Payables declined from Dec. 2023 (€15.33 Mil) to Dec. 2024 (€12.60 Mil) and declined from Dec. 2024 (€12.60 Mil) to Dec. 2025 (€8.84 Mil).

Adagene Other Current Payables Related Terms

Adagene Other Current Payables Historical Data

* Premium members only.

The historical data trend for Adagene's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adagene Other Current Payables Chart

Adagene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial 9.26 18.24 15.33 12.60 8.84

Adagene Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.33 16.10 12.60 12.53 8.84
FRA:978
42GF Score
Adagene Inc FRA:978
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adagene Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €8.84 Mil mean?
Adagene (FRA:978) has a Other Current Payables of €8.84 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Adagene and its competitors.
Is Adagene's Other Current Payables too high?
Adagene's current Other Current Payables is €8.84 Mil. Overall, Adagene has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Adagene's Other Current Payables compare to RNAC and LYEL?
Adagene's Other Current Payables of €8.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Adagene and its competitors. Adagene's current Other Current Payables is €8.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagene stock overvalued right now?
Adagene (FRA:978) has a current Other Current Payables of €8.84 Mil. The stock's GF Value™ is €11.95, compared to a current price of €3.26 — trading 72.7% below its estimated fair value. The current Other Current Payables is €8.84 Mil. Adagene's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Adagene (FRA:978), the current Other Current Payables is €8.84 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adagene (FRA:978) Overvalued in 2026?

Based on GuruFocus' analysis, Adagene stock appears to be undervalued. The current stock price of €3.26 is trading 72.7% below its estimated GF Value™ of €11.95.

Key valuation signals for FRA:978:

  • Other Current Payables: €8.84 Mil
  • GF Value™: €11.95 vs. price of €3.26 (72.7% below fair value)
  • GF Score™: 42/100 with 3 warning signs

No single metric tells the full story. See the FRA:978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adagene Business Description

Other Exchanges ADAG:USA
Address Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
42GF Score

Get the complete analysis for FRA:978

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.26
Price
€11.95
GF Value